Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
Scientists have developed a new technology to efficiently isolate a specific subset of gut bacteria from fecal samples that are recognized by IgA antibodies. These 'IgA-coated' bacteria are associated ...